You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Apothecon Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for APOTHECON, and what generic and branded alternatives to APOTHECON drugs are available?

APOTHECON has one hundred and fourteen approved drugs.

There are three tentative approvals on APOTHECON drugs.

Summary for Apothecon

US Patents:	0
Tradenames:	78
Ingredients:	47
NDAs:	114

Drugs and US Patents for Apothecon

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	ENALAPRIL MALEATE	enalapril maleate	TABLET;ORAL	075583-003	Aug 22, 2000		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	KANTREX	kanamycin sulfate	INJECTABLE;INJECTION	061901-003	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	TOBRAMYCIN SULFATE	tobramycin sulfate	INJECTABLE;INJECTION	064021-001	May 31, 1994		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	PRINCIPEN	ampicillin/ampicillin trihydrate	CAPSULE;ORAL	062888-002	Mar 4, 1988		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	NAFCILLIN SODIUM	nafcillin sodium	INJECTABLE;INJECTION	061984-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	AMPICILLIN SODIUM	ampicillin sodium	INJECTABLE;INJECTION	062860-002	Feb 5, 1988		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Apothecon	AMIKIN	amikacin sulfate	INJECTABLE;INJECTION	062311-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Apothecon

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apothecon	CAPOZIDE 50/25	captopril; hydrochlorothiazide	TABLET;ORAL	018709-003	Oct 12, 1984	4,105,776	⤷ Subscribe
Apothecon	CAPOZIDE 25/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-001	Oct 12, 1984	4,217,347	⤷ Subscribe
Apothecon	CAPOZIDE 50/15	captopril; hydrochlorothiazide	TABLET;ORAL	018709-004	Oct 12, 1984	4,217,347	⤷ Subscribe
Apothecon	STADOL PRESERVATIVE FREE	butorphanol tartrate	INJECTABLE;INJECTION	017857-001	Approved Prior to Jan 1, 1982	3,819,635	⤷ Subscribe
Apothecon	CAPOZIDE 25/25	captopril; hydrochlorothiazide	TABLET;ORAL	018709-002	Oct 12, 1984	4,217,347	⤷ Subscribe
Apothecon	CAPOZIDE 50/25	captopril; hydrochlorothiazide	TABLET;ORAL	018709-003	Oct 12, 1984	4,217,347	⤷ Subscribe
Apothecon	CAPOZIDE 25/25	captopril; hydrochlorothiazide	TABLET;ORAL	018709-002	Oct 12, 1984	4,105,776	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.